Croma-Pharma boosts market share & cataract portfolio

Article

Austrian pharmaceutical firm Croma-Pharma has acquired two companies, thus strengthening its cataract surgery portfolio and, according to the firm, moving it into the top five list of companies operating in the European ophthalmic market.

Austrian pharmaceutical firm Croma-Pharma has acquired two companies, thus strengthening its cataract surgery portfolio and, according to the firm, moving it into the top five list of companies operating in the European ophthalmic market.

Specifically, the firm has now completed the acquisitions of Cornéal Laboratoir and Xcelens.

Cornéal has a strong line of products for anterior and posterior surgery, such as viscolelastic fluids, IOLs and medical devices. Xcelens, despite only being founded in 2003, also has a reputation as a leading provider in the cataract surgery field, with its main interest lying in export.

These acquisitions have now made Croma-Pharma a one-stop provider of cataract surgery products.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.